RankAlpha logo

VSTM

AI Memo

Verastem

As of 2026-08-09/Confidence medium
Open tickerBack to Memos
Data freshness
AI Memo
As of 2026-08-09 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action
—
Confidence
medium
Horizon
—
Key catalyst
VS-7375 October clinical update • 2026-11-07
Base target: $8 / p=50% prob
Biggest risk
The valuation is highly sensitive to October clinical differentiation, enrollment execution, and the ability to make the LGSOC franchise self-sustaining. Funding extends runway but does not eliminate clinical, commercial, or potential dilution risk; analyst revisions and consensus-surprise data are unavailable.
Invalidation
Break below $5 or thesis failure.
What would change my mind?
Commercial revenue is showing traction, funding reduces near-term financing pressure, and the October VS-7375 update could provide a material clinical validation point. The positive deterministic prior is supported by strong primary-source coverage, but the thesis remains event-driven.
Research note
Recommendation
—
Confidence
medium
As of
2026-08-09
Base target
$8
p=50%
Bull target
$11
p=25%
Bear target
$5
p=25%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets
  • Extended non-dilutive funding runway
  • Commercial revenue is showing traction, funding reduces near-term financing pressure, and the October VS-7375 update could provide a material clinical validation point.
  • The positive deterministic prior is supported by strong primary-source coverage, but the thesis remains event-driven.
BearKey bullets
  • Commercial uptake, refills, reimbursement, and adverse-event management may not support the self-sufficiency target.
  • October VS-7375 data may fail to confirm sufficient response, durability, safety, or differentiation.
  • Peer comparability and analyst coverage are limited, and post-earnings estimate or target revisions are unavailable.
WatchKey bullets
  • VS-7375 October clinical update

Summary

High-level snapshot

Recommendation
-
Model confidence
medium
Timeframe
-
Asset
Equity
Trigger
-
Base case: $8 (p=50%)
Target spread vs base: +35% / -39%
Scenario probabilities
Bull Target: $11 (p=25%)Base Target: $8 (p=50%)Bear Target: $5 (p=25%)
Commentary
Recent news tone is moderately constructive after the Q2 update, driven by commercial revenue, funding, and the October clinical-data catalyst. Social coverage, options data, short interest, employee sentiment, and post-print analyst revisions are unavailable; missing data is not treated as positive evidence.
As of 2026-08-09 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case
Commercial revenue is showing traction, funding reduces near-term financing pressure, and the October VS-7375 update could provide a material clinical validation point. The positive deterministic prior is supported by strong primary-source coverage, but the thesis remains event-driven.
Bear Case
The valuation is highly sensitive to October clinical differentiation, enrollment execution, and the ability to make the LGSOC franchise self-sustaining. Funding extends runway but does not eliminate clinical, commercial, or potential dilution risk; analyst revisions and consensus-surprise data are unavailable.

Drivers

Scannable catalysts and supporting factors

  • Extended non-dilutive funding runway

Scenarios

Bull Target (Scenario probability)
$11 / p=25% prob
Base Target (Scenario probability)
$8 / p=50% prob
Bear Target (Scenario probability)
$5 / p=25% prob
Analysis 2026-08-09 · RankAlpha Sentiment Codex
Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)
0.45
Social Sentiment (7d)
0.00

Events

Other notable items detected

  • EVENT2026-11-07
    VS-7375 October clinical update
    The company reported first patients dosed in three Phase 2 registration-directed studies across pancreatic, non-small-cell lung, and colorectal cancers, with additional clinical data expected in October and enrollment targeted for completion by year-end. [#SEC-8K-2026-08-06]
    Prob 70.00% • Move 20.00% • Priced-in 35.00%
  • EVENT2026-12-31
    Commercial uptake and LGSOC self-sufficiency
    Q2 AVMAPKI FAKZYNJA CO-PACK net product revenue was $25.1 million, and management expects the LGSOC business to become self-sustaining by the end of 2026. [#SEC-8K-2026-08-06]
    Prob 60.00% • Move 15.00% • Priced-in 50.00%

Short-term Catalysts

Next few weeks

No short-term catalysts

Long-term Catalysts

Months to a year

  • Extended non-dilutive funding runway
    2027-08-09
    The company reported up to $75 million of royalty financing, $136.4 million of quarter-end cash and pro forma cash of $201.4 million, with runway expected into the second half of 2027. [#SEC-8K-2026-08-06]
    Prob 75% • Move 10% • Priced-in 60%

Risks

  • Commercial uptake, refills, reimbursement, and adverse-event management may not support the self-sufficiency target.
  • October VS-7375 data may fail to confirm sufficient response, durability, safety, or differentiation.
  • Peer comparability and analyst coverage are limited, and post-earnings estimate or target revisions are unavailable.
  • The company remains dependent on continued execution and future financing or strategic transactions despite the extended runway.

Peers

SymbolSummary
CRMDCloser market-cap and sector comparator, but not a validated direct peer for VSTM's oncology pipeline and commercial franchise.
ALTLoose sector and market-cap comparator; the packet does not establish a direct indication or commercial-product match.

Sources

Internal and external references used in this analysis

  • Model source: RankAlpha Sentiment Codex
  • Analysis date: 2026-08-09